212 related articles for article (PubMed ID: 31077681)
21. Primary cross-resistance to BRAFV600E-, MEK1/2- and PI3K/mTOR-specific inhibitors in BRAF-mutant melanoma cells counteracted by dual pathway blockade.
Penna I; Molla A; Grazia G; Cleris L; Nicolini G; Perrone F; Picciani B; Del Vecchio M; de Braud F; Mortarini R; Anichini A
Oncotarget; 2016 Jan; 7(4):3947-65. PubMed ID: 26678033
[TBL] [Abstract][Full Text] [Related]
22. MicroRNA-211 Modulates the DUSP6-ERK5 Signaling Axis to Promote BRAF
Lee B; Sahoo A; Sawada J; Marchica J; Sahoo S; Layng FIAL; Finlay D; Mazar J; Joshi P; Komatsu M; Vuori K; de Jong PR; Ray A; Perera RJ
J Invest Dermatol; 2021 Feb; 141(2):385-394. PubMed ID: 32888955
[TBL] [Abstract][Full Text] [Related]
23. Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors.
Wilson TR; Fridlyand J; Yan Y; Penuel E; Burton L; Chan E; Peng J; Lin E; Wang Y; Sosman J; Ribas A; Li J; Moffat J; Sutherlin DP; Koeppen H; Merchant M; Neve R; Settleman J
Nature; 2012 Jul; 487(7408):505-9. PubMed ID: 22763448
[TBL] [Abstract][Full Text] [Related]
24. Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance.
Das Thakur M; Salangsang F; Landman AS; Sellers WR; Pryer NK; Levesque MP; Dummer R; McMahon M; Stuart DD
Nature; 2013 Feb; 494(7436):251-5. PubMed ID: 23302800
[TBL] [Abstract][Full Text] [Related]
25. Resistance to BRAF-targeted therapy in melanoma.
Sullivan RJ; Flaherty KT
Eur J Cancer; 2013 Apr; 49(6):1297-304. PubMed ID: 23290787
[TBL] [Abstract][Full Text] [Related]
26. HSP90 Inhibition Overcomes Resistance to Molecular Targeted Therapy in BRAFV600E-mutant High-grade Glioma.
Sasame J; Ikegaya N; Kawazu M; Natsumeda M; Hayashi T; Isoda M; Satomi K; Tomiyama A; Oshima A; Honma H; Miyake Y; Takabayashi K; Nakamura T; Ueno T; Matsushita Y; Iwashita H; Kanemaru Y; Murata H; Ryo A; Terashima K; Yamanaka S; Fujii Y; Mano H; Komori T; Ichimura K; Cahill DP; Wakimoto H; Yamamoto T; Tateishi K
Clin Cancer Res; 2022 Jun; 28(11):2425-2439. PubMed ID: 35344043
[TBL] [Abstract][Full Text] [Related]
27.
Kulkarni A; Al-Hraishawi H; Simhadri S; Hirshfield KM; Chen S; Pine S; Jeyamohan C; Sokol L; Ali S; Teo ML; White E; Rodriguez-Rodriguez L; Mehnert JM; Ganesan S
Clin Cancer Res; 2017 Sep; 23(18):5631-5638. PubMed ID: 28539463
[No Abstract] [Full Text] [Related]
28. Clinical Development of BRAF plus MEK Inhibitor Combinations.
Subbiah V; Baik C; Kirkwood JM
Trends Cancer; 2020 Sep; 6(9):797-810. PubMed ID: 32540454
[TBL] [Abstract][Full Text] [Related]
29. Targeted inhibition of BRAF kinase: opportunities and challenges for therapeutics in melanoma.
Pérez-Lorenzo R; Zheng B
Biosci Rep; 2012 Feb; 32(1):25-33. PubMed ID: 21981139
[TBL] [Abstract][Full Text] [Related]
30. Spatio-Genetic and phenotypic modelling elucidates resistance and re-sensitisation to treatment in heterogeneous melanoma.
Hodgkinson A; Le Cam L; Trucu D; Radulescu O
J Theor Biol; 2019 Apr; 466():84-105. PubMed ID: 30503930
[TBL] [Abstract][Full Text] [Related]
31. Intermittent treatment of BRAF
Kavran AJ; Stuart SA; Hayashi KR; Basken JM; Brandhuber BJ; Ahn NG
Proc Natl Acad Sci U S A; 2022 Mar; 119(12):e2113535119. PubMed ID: 35290123
[TBL] [Abstract][Full Text] [Related]
32. Resistance to combination BRAF and MEK inhibition in metastatic melanoma: Where to next?
Welsh SJ; Rizos H; Scolyer RA; Long GV
Eur J Cancer; 2016 Jul; 62():76-85. PubMed ID: 27232329
[TBL] [Abstract][Full Text] [Related]
33. Mechanisms and strategies to overcome resistance to molecularly targeted therapy for melanoma.
Lim SY; Menzies AM; Rizos H
Cancer; 2017 Jun; 123(S11):2118-2129. PubMed ID: 28543695
[TBL] [Abstract][Full Text] [Related]
34. miR-146a-5p impairs melanoma resistance to kinase inhibitors by targeting COX2 and regulating NFkB-mediated inflammatory mediators.
Vergani E; Dugo M; Cossa M; Frigerio S; Di Guardo L; Gallino G; Mattavelli I; Vergani B; Lalli L; Tamborini E; Valeri B; Gargiuli C; Shahaj E; Ferrarini M; Ferrero E; Gomez Lira M; Huber V; Del Vecchio M; Sensi M; Leone BE; Santinami M; Rivoltini L; Rodolfo M; Vallacchi V
Cell Commun Signal; 2020 Sep; 18(1):156. PubMed ID: 32967672
[TBL] [Abstract][Full Text] [Related]
35. Kinase inhibitor library screening identifies synergistic drug combinations effective in sensitive and resistant melanoma cells.
Margue C; Philippidou D; Kozar I; Cesi G; Felten P; Kulms D; Letellier E; Haan C; Kreis S
J Exp Clin Cancer Res; 2019 Feb; 38(1):56. PubMed ID: 30728057
[TBL] [Abstract][Full Text] [Related]
36. ER Translocation of the MAPK Pathway Drives Therapy Resistance in BRAF-Mutant Melanoma.
Ojha R; Leli NM; Onorati A; Piao S; Verginadis II; Tameire F; Rebecca VW; Chude CI; Murugan S; Fennelly C; Noguera-Ortega E; Chu CT; Liu S; Xu X; Krepler C; Xiao M; Xu W; Wei Z; Frederick DT; Boland G; Mitchell TC; Karakousis GC; Schuchter LM; Flaherty KT; Zhang G; Herlyn M; Koumenis C; Amaravadi RK
Cancer Discov; 2019 Mar; 9(3):396-415. PubMed ID: 30563872
[TBL] [Abstract][Full Text] [Related]
37. Optimising the combination dosing strategy of abemaciclib and vemurafenib in BRAF-mutated melanoma xenograft tumours.
Tate SC; Burke TF; Hartman D; Kulanthaivel P; Beckmann RP; Cronier DM
Br J Cancer; 2016 Mar; 114(6):669-79. PubMed ID: 26978007
[TBL] [Abstract][Full Text] [Related]
38. RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E).
Poulikakos PI; Persaud Y; Janakiraman M; Kong X; Ng C; Moriceau G; Shi H; Atefi M; Titz B; Gabay MT; Salton M; Dahlman KB; Tadi M; Wargo JA; Flaherty KT; Kelley MC; Misteli T; Chapman PB; Sosman JA; Graeber TG; Ribas A; Lo RS; Rosen N; Solit DB
Nature; 2011 Nov; 480(7377):387-90. PubMed ID: 22113612
[TBL] [Abstract][Full Text] [Related]
39. [vestigation of molecular factors determining BRAF-inhibitor sensitivity in solid tumors].
Molnár E
Magy Onkol; 2020 Mar; 64(1):76-78. PubMed ID: 32181767
[TBL] [Abstract][Full Text] [Related]
40. Clinical Implications of Acquired BRAF Inhibitors Resistance in Melanoma.
Savoia P; Zavattaro E; Cremona O
Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33419275
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
